Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(03): 335-339
DOI: 10.4103/ijmpo.ijmpo_166_18
Original Article

Predictors of Survival in Children with Osteogenic Sarcoma Undergoing Limb Salvage Surgery: Experience from a Tertiary Cancer Center in Rural India

Vineetha Raghavan
Department of Clinical Hematology and Medical Oncology, Malabar Cancer Centre, Kannur, Kerala, India
,
TK Jithin
Department of Clinical Hematology and Medical Oncology, Malabar Cancer Centre, Kannur, Kerala, India
,
Vinin V Narayanan
Department of Radiation Oncology, Malabar Cancer Centre, Kannur, Kerala, India
,
Sangeetha K Nayanar
Department of Oncopathology, Malabar Cancer Centre, Kannur, Kerala, India
,
Satheesan Balasubrahmanian
Department of Surgical Oncology, Malabar Cancer Centre, Kannur, Kerala, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
   Permissions and Reprints

Abstract

Context: Osteogenic Sarcoma (OGS) is the fifth most common malignancy among adolescents aged 15–19. With multimodality therapy, the long-term survival has improved from 16% in the prechemotherapy era to around 70% in the postchemotherapy era. Aim: This study aims to determine the clinical profile and survival of children with OGS being treated with limb-salvage surgery (LSS). Subjects and Methods: This is a retrospective analysis of all cases of OGS (age ≤ 19) who underwent LSS at our center between June 2009 and February 2017. Baseline characteristics were noted and multivariate analysis was performed for various variables to identify predictors of survival. Results: Among 44 cases studied majority were boys (n = 27). Ninety-three percentage (n = 41) were adolescents. Stage 2 disease was 75% and Stage 3 disease was 25%. The estimated 3-year overall survival (OS) was 69% (95% confidence interval [CI] 55–86) and the estimated 3-year event-free survival (EFS) was 55% (95% CI = 41–74). OS was significantly improved in patients with >90% necrosis postneoadjuvant chemotherapy (NACT) when compared with <90% necrosis (3-year OS = 88% vs. 51%,P= 0.01) and in patients who received ≤4 cycles NACT versus >4 cycles (78% vs. 60%,P= 0.04). EFS was significantly better in patients without lung metastasis at presentation (61% vs. 29%,P= 0.04), Stage 2 disease (59% vs. 38%,P= 0.04) and >90% necrosis in the tumor post-NACT (69% vs. 35%,P= 0.02). Conclusion: Significant response to NACT predicted improved OS and EFS in children with OGS treated with LSS.

Keywords

Limb salvage surgery - osteosarcoma - prognostic factors


Publication History

Received: 26 July 2018

Accepted: 02 January 2020

Article published online:
28 June 2021

© 2020. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Ries LA, Smith MA, Gurney JG, Linet M, Tamra T, Young JL. et al.editors. Cancer. Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995. Bethesda, MD: National Cancer Institute, SEER Program. NIH Pub.No.99-4649; 1999
  • 2 Anninga JK, Gelderblom H, Fiocco M, Kroep JR, Taminiau AH, Hogendoorn PC. et al. Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?. Eur J Cancer 2011; 47: 2431-45
    CrossrefPubMedGoogle Scholar
  • 3 Peabody TD, Gibbs CPJr, Simon MA. Evaluation and staging of musculoskeletal neoplasms. J Bone Joint Surg Am 1998; 80: 1204-18
    CrossrefPubMedGoogle Scholar
  • 4 Enneking WF. A system for evaluation of the surgical management of musculoskeletal tumors. In: Enneking WF. editors Limb Salvage in Musculoskeletal Oncology. New York: Churchill Livingstone; 1987. p. 145
    Google Scholar
  • 5 Goorin AM, Schwartzentruber DJ, Devidas M, Gebhardt MC, Ayala AG, Harris MB. et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 2003; 21: 1574-80
    CrossrefPubMedGoogle Scholar
  • 6 Bacci G, Forni C, Longhi A, Ferrari S, Mercuri M, Bertoni F. et al. Local recurrence and local control of non-metastatic osteosarcoma of the extremities: A 27-year experience in a single institution. J Surg Oncol 2007; 96: 118-23
    CrossrefPubMedGoogle Scholar
  • 7 Grimer RJ, Taminiau AM, Cannon SR. et al. Surgical Subcommitte of the European Osteosarcoma Intergroup. Surgical outcomes in osteosarcoma. J Bone Joint Surg Br 2002; 84: 395-400
    CrossrefPubMedGoogle Scholar
  • 8 Wittig JC, Bickels J, Kellar-Graney KL, Kim FH, Malawer MM. Osteosarcoma of the proximal humerus: Long-term results with limb-sparing surgery. Clin Orthop Relat Res 2002; 397: 156-76
    CrossrefPubMedGoogle Scholar
  • 9 Sukumaran RK, Rajeshwari B, Sugath S, Chellappan SG, Thankamony P, Parukuttyamma K. Methotrexate free chemotherapy and limb salvage surgery for paediatric osteosarcoma in India. Indian J Orthop 2018; 52: 58-64
    CrossrefPubMedGoogle Scholar
  • 10 Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: Current treatment and a collaborative pathway to success. J Clin Oncol 2015; 33: 3029-35
    CrossrefPubMedGoogle Scholar
  • 11 Patel SJ, Lynch JWJr, Johnson T, Carroll RR, Schumacher C, Spanier S. et al Dose-intense ifosfamide/doxorubicin/cisplatin based chemotherapy for osteosarcoma in adults. Am J Clin Oncol 2002; 25: 489-95
    CrossrefPubMedGoogle Scholar
  • 12 Piperno-Neumann S, Bui B, Blay J, Roché H, Pichon F, Peny A. et al. A multicentric prospective study of intensive induction chemotherapy (API-AI) in localized osteosarcoma patients: Results of a phase II trial coordinated by the French Sarcoma Group (FSG) and the FNCLCC BECT. J Clin Oncol 2006; 24 Suppl 18: 9521
    CrossrefGoogle Scholar
  • 13 Tunn PU, Reichardt P. Chemotherapy for osteosarcoma without high-dose methotrexate: A 12-year follow-up on 53 patients. Onkologie 2007; 30: 228-32
    PubMedGoogle Scholar
  • 14 Assi H, Missenard G, Terrier P, Le PechouxC, Bonvalot S, Vanel D. et al. Intensive induction chemotherapy without methotrexate in adult patients with localized osteosarcoma: Results of the Institut Gustave-Roussy phase II trial. Curr Oncol 2010; 17: 23-31
    CrossrefPubMedGoogle Scholar
  • 15 Bajpai J, Chandrasekharan A, Talreja V, Simha V, Chandrakanth MV, Rekhi B. et al. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'. Eur J Cancer 2017; 85: 49-58
    CrossrefPubMedGoogle Scholar
  • 16 Daw NC, Neel MD, Rao BN, Billups CA, Wu J, Jenkins JJ. et al. Frontline treatment of localized osteosarcoma without methotrexate: Results of the St. Jude Children's Research Hospital OS99 trial. Cancer 2011; 117: 2770-8
    CrossrefPubMedGoogle Scholar
  • 17 Nataraj V, Rastogi S, Khan SA, Sharma MC, Agarwala S, Vishnubhatla S. et al. Prognosticating metastatic osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate and delayed metastasectomy: A single center experience of 102 patients. Clin Transl Oncol 2016; 18: 937-44
    CrossrefPubMedGoogle Scholar
  • 18 Shirke-Satpute SN, Rekhi B, Desai SS, Puri A, Agarwal M, Jambhekar NA. Correlation of MDM2, p53 and MIB-1 Expression with Response to Neoadjuvant Chemotherapy in High-Grade Extremity Osteosarcomas and Clinical Outcome.In: Laboratory Investigation. Nature Publishing Group 75 Varick ST, 9th Flr, New York: 10013-1917 USA; 2013.p.20A
  • 19 Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K. et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20: 776-90
    CrossrefPubMedGoogle Scholar
  • 20 Bacci G, Bertoni F, Longhi A, Ferrari S, Forni C, Biagini R. et al. Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer 2003; 97: 3068-75
    CrossrefPubMedGoogle Scholar
  • 21 Vijayanarasimha D, Nayanar SK, Vikram S, Patil VM, Babu S, Satheesan B. Clinico-pathological Study of Limb Salvage Surgery for Osteosarcoma: Experience in a Rural Cancer Center. Indian J Surg Oncol 2017; 8: 136-41
    CrossrefPubMedGoogle Scholar